Evaluating the effects of different doses of ursodeoxycholic acid on neonatal jaundice

Area of Science:

• Neonatal Medicine
• Pediatric Gastroenterology
• Pharmacology

Background:

• Neonatal jaundice is a common cause of hospitalization.
• Effective treatments for neonatal jaundice are crucial for infant health.
• Ursodeoxycholic acid (UDCA) is being investigated for its potential in managing neonatal jaundice.

Purpose of the Study:

• To evaluate the efficacy of different doses of ursodeoxycholic acid (UDCA) when used as an adjunct to phototherapy for treating neonatal jaundice.
• To compare the impact of UDCA at 5 mg/kg and 7.5 mg/kg doses on bilirubin levels and treatment duration.

Main Methods:

• A randomized controlled trial involving 120 newborns hospitalized for phototherapy.
• Participants were assigned to three groups: phototherapy with UDCA (5 mg/kg), phototherapy with UDCA (7.5 mg/kg), or phototherapy with placebo.
• Evaluated outcomes included serum bilirubin levels, duration of phototherapy, and length of hospital stay.

Main Results:

• All groups had similar admission bilirubin levels (around 19.5 mg/dl).
• Both UDCA doses significantly reduced bilirubin levels compared to placebo (p=0.000).
• The 7.5 mg/kg UDCA group showed significantly shorter phototherapy duration and hospital stay (p=0.000).

Conclusions:

• UDCA, when added to phototherapy, effectively lowers bilirubin levels and reduces hospital stay in neonatal hyperbilirubinemia.
• The 7.5 mg/kg dose of UDCA demonstrated superior efficacy in reducing treatment duration and length of hospitalization.
• Further research with larger sample sizes is recommended to establish routine UDCA use for neonatal jaundice.